First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending Dose And Extended Infusion of PF 07304814 In Hospitalized Participants With COVID-19.

Open to people ages 18-75

1. Male or female participants between the ages of 18 and 75 years.
2. Confirmed SARS-CoV-2 infection as determined by standard RT- PCR assay.
3. Hospitalized for COVID-19, with mild or moderate disease (8-point ordinal scale categories 4 to 7).
4. Symptoms consistent with mild or moderate COVID-19 indicated by at least 1 of the following: fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, shortness of breath (at rest or with exertion), or dyspnea.
5. Total body weight >=50 kg (110 lb), BMI <35 kg/m2.

1. Evidence of critical illness, defined by at least one of the following: Respiratory failure, Multi-organ dysfunction/failure, Cardiac failure or septic shock
2. Participants with pre-existing moderate to severe cardiovascular disease, uncontrolled diabetes, or severe asthma or severe COPD.
3. Participants with a known medical history of recent acute or chronic liver disease (other than NASH), chronic or active hepatitis B or C infection, or primary biliary cirrhosis.
4. Participants with known HIV infection.
5. Participants with a known medical history of ischemic heart disease, heart failure, dysrhythmia or other pre-existing cardiac condition.
6. Participants with a known medical history of recurrent seizures.
7. Confirmed concurrent active systemic infection other than COVID-19.
8. Current diagnosis of cancer, unless in remission and untreated.
9. Other medical or psychiatric condition including recent or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation
10. . Previous administration with any investigational drug (including Remdesivir, convalescent sera or Monoclonal antibody treatment for COVID-19 if not local standard of care) within 30 days.